Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders
Objective: The use of fetal hemoglobin (HbF) inducer drugs is considered as a novel approach in treatment of β-hemoglobinopathies, especially β- thalassemia and sickle cell disease. HbF inducers including hydroxyurea, histone deacetylase (HDAC) inhibitor agents such as sodium butyrate, azacitidine,...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Tehran University of Medical Sciences
2013-07-01
|
Series: | International Journal of Hematology-Oncology and Stem Cell Research |
Subjects: | |
Online Access: | http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/405/430 |
id |
doaj-ee94c8037bf341fe828390eeb22938d8 |
---|---|
record_format |
Article |
spelling |
doaj-ee94c8037bf341fe828390eeb22938d82020-11-25T04:02:39ZengTehran University of Medical SciencesInternational Journal of Hematology-Oncology and Stem Cell Research2008-30092008-22072013-07-01734653Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy DisordersFatemeh SalariMohammad ShahjahaniSeyed Ahmad HosseiniAli Dehghani FardKaveh JasebObjective: The use of fetal hemoglobin (HbF) inducer drugs is considered as a novel approach in treatment of β-hemoglobinopathies, especially β- thalassemia and sickle cell disease. HbF inducers including hydroxyurea, histone deacetylase (HDAC) inhibitor agents such as sodium butyrate, azacitidine, decitabine and new immunomodulator drugs like pomalidomide, lenalidomide and thalidomide can reduce α-globin chain production in erythroid progenitors and improve α: β chain imbalance, the most crucial complication of β-thalassemia.Materials and Methods: In this article, we reviewed more than 40 articles published from 1979 to 2012 in the field of fetal hemoglobin augmentation.Results: Recent studies suggest the synergistic effect of drug combinations in efficient induction of fetal hemoglobin and gene over-expression.Conclusion: It seems that drugs which act with different molecular and epigenetic mechanisms have proper synergistic effects in fetal hemoglobin induction and gene over-expressionhttp://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/405/430Fetal Hemoglobinβ-hemoglobinopathiesHistone Deacetylase |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Fatemeh Salari Mohammad Shahjahani Seyed Ahmad Hosseini Ali Dehghani Fard Kaveh Jaseb |
spellingShingle |
Fatemeh Salari Mohammad Shahjahani Seyed Ahmad Hosseini Ali Dehghani Fard Kaveh Jaseb Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders International Journal of Hematology-Oncology and Stem Cell Research Fetal Hemoglobin β-hemoglobinopathies Histone Deacetylase |
author_facet |
Fatemeh Salari Mohammad Shahjahani Seyed Ahmad Hosseini Ali Dehghani Fard Kaveh Jaseb |
author_sort |
Fatemeh Salari |
title |
Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders |
title_short |
Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders |
title_full |
Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders |
title_fullStr |
Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders |
title_full_unstemmed |
Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders |
title_sort |
evaluation of novel fetal hemoglobin inducer drugs in treatment of β-hemoglobinopathy disorders |
publisher |
Tehran University of Medical Sciences |
series |
International Journal of Hematology-Oncology and Stem Cell Research |
issn |
2008-3009 2008-2207 |
publishDate |
2013-07-01 |
description |
Objective: The use of fetal hemoglobin (HbF) inducer drugs is considered as a novel approach in treatment of β-hemoglobinopathies, especially β- thalassemia and sickle cell disease. HbF inducers including hydroxyurea, histone deacetylase (HDAC) inhibitor agents such as sodium butyrate, azacitidine, decitabine and new immunomodulator drugs like pomalidomide, lenalidomide and thalidomide can reduce α-globin chain production in erythroid progenitors and improve α: β chain imbalance, the most crucial complication of β-thalassemia.Materials and Methods: In this article, we reviewed more than 40 articles published from 1979 to 2012 in the field of fetal hemoglobin augmentation.Results: Recent studies suggest the synergistic effect of drug combinations in efficient induction of fetal hemoglobin and gene over-expression.Conclusion: It seems that drugs which act with different molecular and epigenetic mechanisms have proper synergistic effects in fetal hemoglobin induction and gene over-expression |
topic |
Fetal Hemoglobin β-hemoglobinopathies Histone Deacetylase |
url |
http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/405/430 |
work_keys_str_mv |
AT fatemehsalari evaluationofnovelfetalhemoglobininducerdrugsintreatmentofbhemoglobinopathydisorders AT mohammadshahjahani evaluationofnovelfetalhemoglobininducerdrugsintreatmentofbhemoglobinopathydisorders AT seyedahmadhosseini evaluationofnovelfetalhemoglobininducerdrugsintreatmentofbhemoglobinopathydisorders AT alidehghanifard evaluationofnovelfetalhemoglobininducerdrugsintreatmentofbhemoglobinopathydisorders AT kavehjaseb evaluationofnovelfetalhemoglobininducerdrugsintreatmentofbhemoglobinopathydisorders |
_version_ |
1724442698817994752 |